Premium
Aggressive natural killer ( NK )‐cell leukaemia and extranodal NK /T‐cell lymphoma are two distinct diseases that differ in their clinical presentation and cytogenetic findings
Author(s) -
Yang ChingFen,
Hsu ChihYi,
Ho Donald MT
Publication year - 2018
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.13463
Subject(s) - cytopenia , lymphoma , pathology , bone marrow , natural killer cell , pathological , medicine , leukemia , biology , immunology , biochemistry , in vitro , cytotoxicity
Aims Aggressive natural killer ( NK )‐cell leukaemia ( ANKCL ) and extranodal NK /T‐cell lymphoma ( ENKTCL ) with secondary bone marrow involvement are rare bone marrow NK /T‐cell neoplasms and share similar features. This study aimed to distinguish these two entities. Methods and results We studied bone marrow NK /T‐cell neoplasms by classifying them into those with no extramedullary mass (group 1, eight cases) and those with extramedullary mass (group 2, 13 cases). The two groups showed similar clinical presentations and pathological features. Fever and cytopenia were the most common clinical presentations in both groups. The neoplastic cells varied from small and relatively monotonous cells to large pleomorphic cells. In six cases (two in group 1, and four in group 2), the neoplastic infiltrate was inconspicuous, consisting of ≤10% of marrow cells in the interstitium, which were hardly identified by haematoxylin and eosin staining alone. Nearly all patients rapidly died, regardless of the neoplastic infiltrate volume. All of the group 1 patients fulfilled the World Health Organisation 2017 diagnostic criteria of ANKCL , and their survival was significantly worse than that of the group 2 patients ( P = 0.035). In addition, there was a significant association between being in group 1 and chromosome 7 abnormalities. Chromosome 6q deletion, which is commonly reported in ENKTCL , was seen in two of our group 2 patients, and was not observed in any of our group 1 patients. Conclusion ANKCL with no extramedullary mass should be distinguished from ENKTCL with bone marrow involvement, as the former shows distinct outcomes and genetic features.